Cargando…

Diffuse skeletal pain after administration of alendronate

BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaras, Nihal, Rezvani, Aylin
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941618/
https://www.ncbi.nlm.nih.gov/pubmed/20927253
http://dx.doi.org/10.4103/0253-7613.68435
_version_ 1782186920201158656
author Ozaras, Nihal
Rezvani, Aylin
author_facet Ozaras, Nihal
Rezvani, Aylin
author_sort Ozaras, Nihal
collection PubMed
description BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. Musculoskeletal pain may be an important side effect in these patients. We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate. CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.
format Text
id pubmed-2941618
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-29416182010-10-06 Diffuse skeletal pain after administration of alendronate Ozaras, Nihal Rezvani, Aylin Indian J Pharmacol Case Report BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. Musculoskeletal pain may be an important side effect in these patients. We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate. CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis. Medknow Publications 2010-08 /pmc/articles/PMC2941618/ /pubmed/20927253 http://dx.doi.org/10.4103/0253-7613.68435 Text en © Indian Journal of Pharmacology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ozaras, Nihal
Rezvani, Aylin
Diffuse skeletal pain after administration of alendronate
title Diffuse skeletal pain after administration of alendronate
title_full Diffuse skeletal pain after administration of alendronate
title_fullStr Diffuse skeletal pain after administration of alendronate
title_full_unstemmed Diffuse skeletal pain after administration of alendronate
title_short Diffuse skeletal pain after administration of alendronate
title_sort diffuse skeletal pain after administration of alendronate
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941618/
https://www.ncbi.nlm.nih.gov/pubmed/20927253
http://dx.doi.org/10.4103/0253-7613.68435
work_keys_str_mv AT ozarasnihal diffuseskeletalpainafteradministrationofalendronate
AT rezvaniaylin diffuseskeletalpainafteradministrationofalendronate